Supplementary Table S3. TEAEs leading to dose modifications (reductions, delays, or interruptions) in patients with or without liver lesion involvement and by CTCAE grade (safety population)

	With Liver Involvement				Without Liver Involvement			
	Normal	Liver Impairment			Normal	Liver Impairment		
	A (n=204)	B (n=210)	C (n=294)	D (n=23)	A (n=336)	B (n=82)	C (n=146)	D (n=11)
Overall, n (%)								
Total	85 (41.7)	114 (54.3)	154 (52.4)	21 (91.3)	146 (43.5)	45 (54.9)	77 (52.7)	5 (45.5)
Grade 1	3 (1.5)	7 (3.3)	8 (2.7)	2 (8.7)	5 (1.5)	4 (4.9)	5 (3.4)	0
Grade 2	21 (10.3)	15 (7.1)	18 (6.1)	0	26 (7.7)	10 (12.2)	16 (11.0)	0
Grade 3	38 (18.6)	53 (25.2)	73 (24.8)	6 (26.1)	73 (21.7)	23 (28.1)	41 (28.1)	4 (36.4)
Grade 4	23 (11.3)	39 (18.6)	55 (18.7)	13 (56.5)	42 (12.5)	8 (9.8)	15 (10.3)	1 (9.1)

Group A, no liver impairment; group B, increased AST and/or ALT only; group C, any abnormality except increased bilirubin; group D, increased bilirubin.

CTCAE, Common Terminology Criteria for Adverse Events; TEAE, treatment-emergent adverse event.